Abstract
This quotation from Shakespeare beautifully describes the signs and symptoms of male hypogonadism. Despite the clear similarities between the effects seen in young men with low testosterone levels and the major changes reported in older males, there has been a reluctance to pursue hormonal replacement therapy in the male. Why is this the case? Although there are clearly many contributory reasons, it seems that the major reason was, until recently, the complete male dominance of the medical profession. Males have had little problem perceiving females, who, as the “other” sex, went through a hormonal change that diminished them as reproductively useful individuals. On the other hand, the very essence of maleness is their virility. The concept that males, too, may have a waning of their sex hormones with age reaches into the deepest taboos of the male psyche. Their macho image was seriously threatened by the hints of this male “imperfection.” It is for this reason that, in the area of sex hormones, we know far more about their effects in females than in males. This stands in stark contrast to most other areas of medicine, in which women have been essentially ignored until recently.
“The seventh age drifts into the lean and slippered pantaloon, His youthful hose well saved, a world too wide For his shrunk shrank and his manly voice Turning again towards childish treble pipes And whistles in his song”
William Shakespeare—As You Like It
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Harman SM, Tsitouras PD. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab 1980;51:35–40.
Baker HW, Burger HG, deKretser DM, Hudson B, O’Connor S, Wang C, et al. Changes in the pituitary-testicular system with age. Clin Endocrinol 1976;5:349–372.
Vermeulen A. Clinical review 24: androgens in the aging male. J Clin Endocrinol Metab 1991;73:221–224.
Sagel J, Distiller LA, Morley JE, Isaacs H, Kay G, Van Der Walt A. Myotonia dystrophica: studies on gonadal function using luteinizing hormone-releasing hormone (LRH). J Clin Endocrinol Metab 1975; 40:1110–1113.
Distiller LA, Morley JE, Sagel J, Pokroy M, Rabkin R. Pituitary-gonadal function in chronic renal failure: the effect of luteinizing hormone-releasing hormone and the influence of dialysis. Metabolism 1975;24:711–720.
Distiller LA, Sagel J, Morley JE, Oxenham E. Assessment of pituitary gonadotropin reserve using luteinizing hormone-releasing hormone (LRH) in states of altered thyroid function. J Clin Endocrinol Metab 1975;40:512–515.
Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab 1984;59:955–962.
Korenman SG, Morley JE, Mooradian AD, Davis SS, Kaiser FE, Silver AJ, Viosca SP, Garza D. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab 1990;71: 963–969.
Tenover JS, Dahl KD, Vale WW, Rivier JE, Bremner WJ. Hormonal responses to a potent gonadotropin hormone-releasing hormone antagonist in normal elderly men. J Clin Endocrinol Metab 1990;71:881–888.
Nankin HR, Calkins JH. Decreased bioavailable testosterone in aging normal and impotent men. J Clin Endocrinol Metab 1986;63:1418–1420.
Morley JE, Kaiser F, Raum WJ, Perry HM 3rd, Flood JF, Jensen J, Silver AJ, Roberts E. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci USA 1997;94:7537–7542.
Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991;73: 1016–1025.
Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 1991;44:671–684.
Kaiser FE, Morley JE. Gonadotropins, testosterone, and the aging male. Neurobiol Aging 1994; 15: 559–563.
Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Morley PM, Stauber PM, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997;46:410–413.
Veldhuis JD, Iranmanesh A, Weltman A. Elements in the pathophysiology of diminished growth hor-mone (GH) secretion in aging humans. Endocrine 1997;7:41–48.
Blackman MR, Tsitouras PD, Harman SM. Reproductive hormones in aging men. Ill: Basal and LHRH-stimulated serum concentrations of the common alpha-subunit of the glycoprotein hormones. J Gerontol 1987;42:476–481.
Veldhuis JD. Altered pulsatile and coordinate secretion of pituitary hormones in aging: evidence of feedback disruption. Aging 1997;9:19–20.
Morley JE, Baranetsky NG, Wingert TD, Carlson HE, Hershman JM, Melmed S, et al. Endocrine effects of naloxone-induced opiate receptor blockade. J Clin Endocrinol Metab 1980;50:251–257.
Billington CJ, Shafer RB, Morley JE. Effects of opioid blockade with nalmefene in older impotent men. Life Sci 1990;47:799–805.
Vermeulen A, Deslypere JP, DeMeirleir K. A new look to the andropause: altered function of the gonadotrophs. J Steroid Biochem 1989;32:163–165.
Vermeulen A. Androgen secretion after age 50 in both sexes. Hormone Res 1983;18:37–42.
Paniagua R, Nistal M, Saez FJ, Fraile B. Ultrastructure of the aging human testis. J Electron Microsc Technique 1991;19:241–260.
Neaves WB, Johnson L, Petty CS. Seminiferous tubules and daily sperm production in older adult men with varied numbers of Leydig cells. Biol Reprod 1987;36:301–308.
Tenover JS, McLachlan RI, Dahl KD, Burger HG, de Kretser DM, Bremner WJ. Decreased serum inhibin levels in normal elderly men: evidence for a decline in Sertoli cell function with aging. J Clin Endocrinol Metab 1988;67:455–459.
Brown-Sequard CE. Effects in man of subcutaneous injections of freshly prepared liquid from guinea pig and dog testes. CR Seances Soc Biol Ser 9 1889;1:415–419.
Brown-Sequard CE. The physiological and therapeutic of animal testicular extract based on several experiments in man. Physiol Norm Pathol 1889;115:739–746.
Carruthers M. Maximizing Manhood. Harper Collins:Hammersmith, London, 1997.
Hamilton D. The Monkey Gland Affair. Chatto and Windus, New York, 1986.
Jensen EV. Remembrance: Gregory Pincus—catalyst for early receptor studies. Endocrinology 1992; 131:1581–1582.
Hoberman JM, Yesalis CE. The history of synthetic testosterone. Sci Am 1995;272:76–81.
Schiavi RC, Schreiner-Engel P, White D, Mandeli J. The relationship between pituitary-gonadal func¬tion and sexual behavior in healthy aging men. Psychosom Med 1991;53:363–374.
Davidson JM, Chen J J, Crapo L, Gray GD, Greenlead WJ, Catania J A. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab 1983;57:71–77.
Money J. The therapeutic use of androgen-depleting hormone. Int Psychiatry Clin 1971;8:165–174.
Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997;82:3793–3796.
Morley JE, Perry HM 3rd, Kaiser FE, Kraenzle D, Jensen J, Houston K, Mattammal M, Perry HM Jr. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993;41:149–152.
Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82:1661–1667.
Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, Ferrando A. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995;269:E820-E826.
Orrell RW, Woodrow DF, Barrett MC, Press M, Dick DJ, Rowe RC, Lane RJ. Testosterone deficiency myopathy. J Royal Soc Med 1995;88:454–456.
Elashoff JD, Jacknow AD, Shain SG, Braunstein GD. Effects of anabolic-androgenic steroids on mus-cular strength. Ann Intern Med 1991;115:387–393.
Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, et al. The effects of supraphys-iologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1–7.
Flood JF, Morley JE. Learning and memory in the SAMP8 mouse. Neurosci Biobehav Rev 1998;22: 1–20.
Flood JF, Farr SA, Kaiser FE, La Regina M, Morley JE. Age-related decrease of plasma testosterone in SAMP8 mice: replacement improves age-related impairment of learning and memory. Physiol Behav 1995;57:669–673.
Morley JE, Kaiser F, Raum WJ, Perry HM 3rd, Flood JF, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci USA 1997;94:7537–7542.
Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci 1994;108:325–332.
Powell DH. Profiles in Cognitive Aging. Harvard University Press, Cambridge, MA, 1994.
Sherwin BB. Sex hormones and psychological functioning in postmenopausal women. Exp Gerontol 1994;29:423–430.
Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75:1092–1098.
Nanjee MN, Rajput-Williams J, Samuel L, Wootton R, Miller NE. Relationships of plasma lipoprotein concentrations to unbound, albumin-bound and sex hormone-binding globulin-bound fractions of gonadal steroids in men. Eur J Clin Invest 1989;19:241–245.
Deutscher S, Bates MW, Caines MJ, LaPorte RE, Puntereri A, Taylor FH. Determinants of lipid and lipoprotein level in elderly men. Atherosclerosis 1986;60:221–229.
Khaw KT, Barrett-Connor E. Endogenous sex hormones, high density lipoprotein cholesterol, and other lipoprotein fractions in men. Arterioscler Thromb 1991 ;11:489–494.
Risssanen J, Hudson R, Ross R. Visceral adiposity, androgens, and plasma lipids in obese men. Metabolism 1994;43:1318–1323.
Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992;2:675–682.
Barrett-Connor EL. Testosterone and risk factors for cardiovascular disease in men. Diabete Metab 1995;21:156–161.
Wu S, Weng X. Therapeutic effect of andriol on serum lipids and apolipoproteins in elderly male coronary heart disease patients. Chin Med Sci J 1992;7:137–141.
Zhao SP, Li XP. The association of low plasma testosterone level with coronary artery disease in Chinese men. Int J Cardiol 1998;63:161–164.
Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994;14:701–706.
Hartnell J, Korenman SG, Viosca SP. Results of testosterone enanthate therapy in older men. Proceedings of the 72nd Annual Meeting of the Endocrine Society, 1990, p. 428.
Barth JD, Jansen H, Hugenholtz PG, Birkenhager JC. Post-heparin lipases, lipids and related hormones in men undergoing coronary arteriography to assess atherosclerosis. Atherosclerosis 1983;48:235–241.
Stephan JJ, Lachman M. Castrated men with bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989;69:523–527.
Foresta C, Ruzza G, Mioni R, Meneghello A, Baccichetti C. Testosterone and bone loss in Klinefelter syndrome. Horm Metab Res 1983;15:56–57.
Ongphiphadhanakul B, Rajatanavin R, Chailurkit L, Piaseu N, Teerarungsikul K, Sirisriro R, Komindr S, Puavilai G. Serum testosterone and its relation to bone mineral density and body composition in normal males. Clin Endocrinol 1995;43:727–733.
Wishart JM, Need AG, Horowitz M, Morris HA, Nordin BE. Effect of age on bone density and bone turnover in men. Clin Endocrinol 1995;42:141–146.
Jackson JA, Riggs MW, Spiekerman AM. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci 1992;304:4–8.
Stanley HL, Schmitt BP, Poses RM, Deiss WP. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc 1991;39:766–771.
McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557–563.
Vatten LJ, Ursin G, Ross RK, Stanczyk FZ, Lobo RA, Harvei S, Jellum E. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev 1997;6:967–969.
Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997;20:605–608.
Monda JM, Myers RP, Bostwick DG, Oesterling JE. The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration. Urology 1995; 46:62–64.
Mermall H, Sothern RB, Kanabrocki EL, Quadri SF, Bremner FW, Nemchausky BA, Scheving LE. Temporal (circadian) and functional relationship between prostate-specific antigen and testosterone in healthy men. Urology 1995;46:45–53.
Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL, Rosner W, Walsh PC. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995;27:25–31.
Group (VACURG) Veterans Administration Cooperative Urology (VACUR). Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011–1027.
Fowler JE Jr, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981;126:372–375.
Thornton MJ, Messenger AG, Elliott K, Randall VA. Effect of androgens on the growth of cultured human dermal papilla cells derived from beard and scalp hair follicles. J Invest Dermatol 1991 ;97:345–358.
Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL, et al. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994;79:703–706.
Tsukamura H, Nagatani S, Cagampang FR, Kawakami S, Maeda K. Corticotropin-releasing hormone mediates suppression of pulsatile luteinizing hormone secretion induced by activation of alpha-adren-ergic receptors in the paraventricular nucleus in female rats. Endocrinology 1994;134:1460–1466.
Sandblom RE, Matsumoto AM, Schoene RB, Lee KA, Giblin EC, BremnerWJ, Pierson DJ. Obstructive sleep apnea syndrome induced by testosterone administration. N Engl J Med 1983;308:508–510.
Morley JE, Krahn DD. Endocrinology for the psychiatrist. In: Nemeroff CB, Loosen PT, eds. Handbook of Clinical Psychoneuroendocrinology. Guilford, New York, 1987, pp. 3–41.
Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15: 212–215.
Place VA, Nichols KC. Transdermal delivery of testosterone with Testoderm to provide a normal circadian patern of testosterone. Ann NY Acad Sci 1991;618:441–449.
Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol 1997;47:727–737.
Jordan WP Jr. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am J Contact Derm 1997;8:108–113.
Arver S, Dobs AS, Meikle AW, Allen RP, Sanders SW, Mazer NA. Improvement of sexual function in testosterone deficient men treated for 1 year with permeation enhanced testosterone transdermal system. J Urol 1996;155:1604–1608.
Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980;51:1335–1339.
Morley JE, Melmed S. Gonadal dysfunction in systemic disorders. Metabolism 1979;28:1051–1073.
Holzman D. Testosterone wasting and AIDS. Mol Med Today 1996;2:93.
Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, Burrows B, et al. Effects of androgen administration in men with the aids wasting syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;129:18–23.
Rabkin JG, Rabkin R, Wagner GJ. Testosterone treatment of clinical hypogonadism in patients with HIV/AIDS. Int J STD AIDS 1997;8:537–545.
Hall GM, Larbre JP, Spector TD, Perry LA, DaSilva JA. A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol 1996;35:568–573.
Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996;156:1173–1177.
Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153–160.
Davis SR, Burger HG. Use of androgens in postmenopausal women. Curr Opin Obstet Gynecol 1997; 9:177–180.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Morley, J.E. (2000). Testosterone. In: Morley, J.E., van den Berg, L. (eds) Endocrinology of Aging. Contemporary Endocrinology, vol 20. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-715-4_9
Download citation
DOI: https://doi.org/10.1007/978-1-59259-715-4_9
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-171-4
Online ISBN: 978-1-59259-715-4
eBook Packages: Springer Book Archive